Fundraising Fox

Eywa

5 known investors

Eywa produces clinical-grade psychedelic compounds — including psilocybin, DMT, 5-MeO-DMT, and bufotenine — as APIs and finished drug products made through biosynthesis for use in scientific research, clinical trials, and commercial mental health applications. It also offers a dual-platform app for therapists and patients to personalize and monitor mental health treatment.

BiotechDigital HealthMental Health

Investors · 5

Draper AssociatesSan Mateo · $500K – $5M
Ganesha LabSantiago · $200K
GRIDXBuenos Aires · $250K
ah! VenturesreportedUnknown · $100K – $120K
F-Prime CapitalreportedCambridge · $3M – $10M

In the news

Eywa Biotech Raises USD 2.5 M Led by Tim Draperlatamrepublic.com · Oct 2025Eywa Pharma bags $30 million in funding, ETHealthworldhealth.economictimes.indiatimes.com · Oct 2016Eywa Pharma raises $30 mn from clutch of investorsbusiness-standard.com · Oct 2016Eywa Pharma raises $30 million | Mintlivemint.com · Oct 2016Digital signal processing startup Eywa Media raises Rs 6.57 crore in seed funding - The Economic Timeseconomictimes.indiatimes.com · Oct 2015Eywa Media raises $1 millionfrom ah! Ventures, PE funds - The Hindu BusinessLinethehindubusinessline.com · Sep 2015

Frequently asked questions

What does Eywa do?
Eywa produces clinical-grade psychedelic compounds — including psilocybin, DMT, 5-MeO-DMT, and bufotenine — as APIs and finished drug products made through biosynthesis for use in scientific research, clinical trials, and commercial mental health applications. It also offers a dual-platform app for therapists and patients to personalize and monitor mental health treatment.
Who are Eywa's investors?
Eywa's investors include Draper Associates, Ganesha Lab, GRIDX, ah! Ventures, F-Prime Capital.